Superoxide and other oxygen radicals produced by activated polymorphonuclear leukocytes (PMN) may be important causes of tissue damage in a number of inflammatory conditions. Therefore, a drug which suppresses PMN responses in vivo is potentially important. In vitro, pentoxifylline (PTOX) inhibits superoxide anion production when PMN are stimulated with an activated complement component (C5a Des Arg) or formyl peptides but only at concentrations not achieved in the circulation. The aim of this study was to determine whether PTOX has an effect on PMN responses in vivo. Superoxide anion production, monitored by lucigenin-enhanced chemiluminescence, was inhibited by 40.5% 8.0%o (n = 8, P < 0.009) for C5a Des Arg and 47.7% 9.6% (n = 8, P < 0.009) for formyl-methionylleucylphenylalanine stimulation 1.5 h after ingestion of 400 mg of PTOX in a slow-release tablet, with some inhibitory effects persisting at 5 h. There was a strong correlation between reduced PMN response to activated complement and plasma concentrations of three PTOX metabolites (P < 0.05), but not with plasma concentrations of the parent drug. In vitro investigations with each of the four methylxanthines showed two of these metabolites to be most effective at reducing PMN respiratory burst activity, lactoferrin release, and the expression of CD11b and CD18 molecules. Furthermore, this in vitro inhibitory activity was achieved at concentrations of metabolites achievable in vivo. The results suggest that PTOX reduces oxygen radical production and protects against unwanted tissue damage in vivo by the action of its metabolites.
Superoxide and other oxygen radicals produced by activated polymorphonuclear leukocytes (PMN) may be important causes of tissue damage in a number of inflammatory conditions. Therefore, a drug which suppresses PMN responses in vivo is potentially important. In vitro, pentoxifylline (PTOX) inhibits superoxide anion production when PMN are stimulated with an activated complement component (C5a Des Arg) or formyl peptides but only at concentrations not achieved in the circulation. The aim of this study was to determine whether PTOX has an effect on PMN responses in vivo. Superoxide anion production, monitored by lucigenin-enhanced chemiluminescence, was inhibited by 40.5% 8.0%o (n = 8, P < 0.009) for C5a Des Arg and 47. 7% 9.6% (n = 8, P < 0.009) for formyl-methionylleucylphenylalanine stimulation 1.5 h after ingestion of 400 mg of PTOX in a slow-release tablet, with some inhibitory effects persisting at 5 h. There was a strong correlation between reduced PMN response to activated complement and plasma concentrations of three PTOX metabolites (P < 0.05), but not with plasma concentrations of the parent drug. In vitro investigations with each of the four methylxanthines showed two of these metabolites to be most effective at reducing PMN respiratory burst activity, lactoferrin release, and the expression of CD11b and CD18 molecules. Furthermore, this in vitro inhibitory activity was achieved at concentrations of metabolites achievable in vivo. The results suggest that PTOX reduces oxygen radical production and protects against unwanted tissue damage in vivo by the action of its metabolites.
Polymorphonuclear leukocytes (PMN) have been implicated in tissue damage following myocardial infarction (19) . These cells are also believed to cause tissue damage in a number of inflammatory conditions, one of the most extensively studied being adult respiratory distress syndrome (23) . Consequently, a drug which reduces the response of PMN to physiological stimuli at sites of inflammation is potentially important. Among such stimuli are the complement component C5a Des Arg and formyl peptides secreted by bacteria (16) . Among the possible toxins released by PMN are reactive oxygen radicals including superoxide anions, hydrogen peroxide, and hydroxyl radicals. Pentoxifylline (PTOX) is a methylxanthine usually prescribed for patients with peripheral or cerebral arterial insufficiency (24) , but it is also effective in healing varicose ulcers, a condition in which PMN-mediated tissue damage may be important (4, 13) . PTOX has been demonstrated in vitro to exert a number of effects on leukocyte function. These include increasing the filterability of whole blood through its effects on leukocytes and increasing the deformability of blood cells (14, 17) . This effect is thought to be due to decreased actin polymerization in cells exposed to the drug. PTOX has been shown to reduce CR3 (CD11b), primary degranulation, and superoxide anion production (5) and inhibit C5a Des Arg-stimulated secondary degranulation (20) . However, the concentrations of PTOX used in these investigations are not achieved in the plasma of patients taking normal therapeutic doses (1, 24 (3) . Therefore, taking the integral chemiluminescence after 28 min allowed for the measurement of both these phases.
To confirm that increased light output was associated with superoxide anion production, we did experiments with control cuvettes containing 50 jig of superoxide dismutase (Sigma Chemical Co.) ml-1, which completely inhibited the chemiluminescence response.
Zymosan-activated serum. A standard supply of ZAS was produced by the method of Fernandez et al. (6) . Briefly, blood was taken from 12 healthy volunteers, placed into serum tubes, and allowed to clot at room temperature. These samples were then centrifuged at 1,000 x g for 15 min, and the serum supernatants were harvested and then pooled together. The pooled serum was incubated with zymosan A (Sigma Chemical Co.) at a concentration of 1 mg ml-1 on a rotating wheel at 37°C for 60 min. The zymosan particles were removed by centrifugation at 1,000 x g for 15 min, and this was followed by ifitration of the supernatant twice through 0.2-p,m-pore-size, sterile, pyrogen-free ifiters (Sartorius). The filtration step was done twice to ensure removal of any residual opsonized zymosan particles. The Measurement of plasma PTOX and metabolites. Plasma levels of the parent drug and its three metabolites were kindly measured by Hoechst UK Limited. Methylxanthines in the plasma were detected by automated capillary gas chromatography with nitrogen-selective detection by the method of Burrows (2) . The metabolites measured were BL-194 (5'-hydroxyhexyl-3,7-dimethylxanthine), MET IV (4'-carboxybutyl-3,7-dimethylxanthine), and MET V (3'-carboxypropyl-3,7-dimethylxanthine).
Limuus amoebocyte lysate assay. All reagents were tested for the presence of endotoxin by the E-Toxate assay (Sigma Chemical Co.). The assay detected endotoxin down to 10 pg ml-. Reagents containing more than 20 pg of contaminating endotoxin ml-1 were not used in any of the experiments.
Statistics. Data are expressed as the means + the standard errors of the mean. Data were compared by the Wilcoxon signed-rank nonparametric test; for determination of correlations between decreased chemiluminescence responses ex vivo after administration of the drug and levels of circulating methylxanthines, the Spearman rank correlation coefficient was used. Values of P < 0.05 for both tests were considered to be significant. While decreased superoxide anion production was associated with peak levels of circulating methyLxanthines, it was not possible to associate the effects with any one of the metabolites in particular. With all the metabolites, there was a correlation (r3 = -0.298, P < 0.05 for BL-194; r, = -0.312, P < 0.05 for MET IV; and r = -0.428, P < 0.04 for MET V) between decreased chemiluminescence and the concentration of each metabolite detectable in the plasma; however, the correlation between superoxide anion production in response to ZAS and the levels of parent drug (rS = -0.208) was not significant. Effect of methylxanthines on PMN superoxide anion production in vitro. To determine whether one or all of the metabolites were more effective at inhibiting PMN function, we tested all four methylxanthines for their ability to affect respiratory burst activity (Fig. 2) . When methylxanthines were added to luminometer cuvettes immediately before or after FMLP stimulation, no effect was observed (data not shown). However, when cells were preincubated with methyixanthines at 37C for 30 min before stimulation with FMLP, all three metabolites tested induced a significant reduction in the amount of chemiluminescence observed at the physiologically relevant concentration of 100 ng ml-V.
None of the concentrations of PTOX used showed this inhibitory activity. These data therefore confirm the ex vivo results which indicated that it was the metabolites and not Effect of 100 ng of methyixanthines ml-l with the addition of 10-6 M FMLP. The results represent the means of seven separate experiments ± SEM. Results were significant at P < 0.04 (*) andp < 0.03 the parent drug that were effective at reducing PMN respiratory burst activity.
Effect of nethinthines on Lfrelease. Figure 3 shows that MET V was the most effective at reducing Lf secretion from cells stimulated by simply warming from 4 to 37°C, and with the additional stimulus of FMLP. Again, the parent drug had no effect on reducing Lf release at any of the concentrations used.
Effect of methylxanthines on CD11b and CD1S expression. As shown in Fig. 4 , the most marked reduction in adhesion molecule expression was seen with MET V. PMN increase their expression of CD11b and CD18 after the cells are warmed (11) , and MET V was effective at reducing this increased expression under these conditions. With the additional stimulus of FMLP, MET V again caused the most marked reduction in CD11b and CD18 expression. (20) and respiratory burst activity (5). PTOX has also been shown to inhibit tumor necrosis factor production from mononuclear cells stimulated with bacterial lipopolysaccharide (21) . It would therefore appear that this particular methyixanthine is capable of down-regulating a number of responses involved in promoting inflammation. However, these and a number of other studies (10, 15, 22) were done with concentrations of PTOX which are unachievable in vivo. In the present study, high concentrations of PTOX (10 pg to 1 mg ml-') could not be achieved in the circulation of subjects receiving one 400-mg slow-release tablet.
In the present study, plasma concentrations of about 100 ng of PTOX ml-1, corresponding to approximately 3 x 10-7 M, were found together with significant depression of PMN response to both ZAS and FMLP stimulation. This conflicts with published in vitro data, which would predict either potentiation of responses or no effect at these concentrations (18) . The slight enhancement seen at 24 h may be a result of the low levels of BL-194 and MET V detected in the plasma at this time point. The implication of the ex vivo data presented here is that part of the effect of PTOX on circulating PMN is due to its metabolites. Of those measured, MET V reached the highest plasma concentrations at 600 ng ml-', approximately 2 x 10-6 M, but this is still much lower than the concentration of the parent drug required for the same effect in vitro. It would seem either that one or more of the metabolites are more active than the parent compound or that the drug and its In vitro, all three metabolites induced a significant reduction of superoxide anion production at the physiologically relevant concentration of 100 ng ml-'. None of the concentrations of PTOX used showed this inhibitory activity. These data therefore confirm the ex vivo results, which indicated that it is the metabolites and not the parent drug that are effective at reducing PMN respiratory burst activity.
PTOX has been used in the treatment of venous leg ulcers, in which it has been shown to improve ulcer healing when used in conjunction with compression bandaging (13) . It is therefore possible that PTOX reduces tissue damage by reducing the production of toxic oxygen radicals. Methylxanthines may also reduce continued inflammation in leg ulcers by reducing the number of PMN in the marginated pool and those entering the tissues. Adhesion of PMN to endothelium is dependent on the expression of CD11b and CD18 molecules on the PMN surface (11, 25) . Of the methylxanthine metabolites tested in vitro, MET V was the most effective at reducing both Lf release and adhesion molecule expression. This suggests that this particular metabolite is effective at reducing the adhesiveness of the PMN by reducing CD11b and CD18 expression and also by inhibiting Lf release. Since Lf is a strongly cationic protein, it may act to negate the electrostatic forces between the PMN and endothelium (8) .
These investigations suggested that MET V is the most effective at reducing PMN activity both in vivo and in vitro because of its effectiveness in vitro and because it was found at the highest concentrations in the plasma.
The mechanism by which methylxanthines depress neutrophil responses is not known. It is usually assumed that they inhibit phosphodiesterase activity as determined by the measurement of increased cyclic AMP levels. However, this effect on cellular cyclic AMP only occurs at concentrations of methyLxanthines far higher than those detected in the plasma. Methylxanthines can also act as antagonists of both Al and A2 adenosine receptors (7) , and it has been suggested that this is the mechanism by which they potentiate neutrophil responses at low concentrations (18) . However, more recent evidence suggests that this is not the mechanism for inhibition of superoxide anion production from PMN when PTOX is used at higher concentrations (22) . The most likely explanation remains that methylxanthines inhibit phosphodiesterase, as increased levels of cyclic AMP certainly reduce PMN responses (12) .
The stimuli used in this study are physiologically relevant. ZAS contains C5a Des Arg, a potent stimulus to PMN via a specific receptor, and this complement component is generated during inflammation. FMLP is one of a family of formyl peptides shown to be secreted by certain bacteria (16) 
